Search GLOW peptide before and after and you get photographs. The published record is one retrospective chart review of 17 knee patients, and its outcome measure was a telephone call.
No study has given BPC-157, TB-500 and GHK-Cu together. Controlled trials of the blend number zero. The nearest human data is a 2021 retrospective review of 17 knee patients at one clinic. 16 were reached by phone. 14 said they felt better. That is 87.5%, and it has no control arm. The placebo response in knee studies runs 30–60%.
What was actually measured
The study people are reaching for is Lee and Padgett, 2021. It is a chart review, not a trial. A single Florida clinic looked back at 17 patients who had received BPC-157 injections into the knee over about a year.
The primary outcome was a phone call at six to twelve months, asking whether the patient felt better. 16 were reachable. 14 said yes.
- No control arm. Nobody got a placebo, a corticosteroid, hyaluronic acid or PRP for comparison.
- No validated outcome measure. No KOOS, no WOMAC, no IKDC, no imaging. The measure was the question the clinic asked.
- Variable follow-up. Six to twelve months is not one timepoint, so the responses are not comparable to each other.
- The clinic surveyed its own patients. Recall bias in that design is well characterized and it runs in one direction.
We take the study apart in full in the BPC-157 knee case series. It is worth reading before treating the number as a result.
That study is not a study of GLOW
Here is the part that gets lost. Those patients were given BPC-157. Four of them received two of the blend’s three compounds. Not one received all three.
So the strongest human number attached to GLOW comes from a study that never administered GLOW. It is borrowed, and it is borrowed from a design that cannot support it.
Controlled trials of the three compounds together number zero, in any species. There is no pharmacokinetic work and no stability data for three peptides in one cake. The GLOW complete guide sets out what is in the vial and what each part has behind it.
Why 87.5% is not an efficacy figure
The number is real. What it means is the problem. Knee pain has one of the largest placebo responses in medicine, and it moves in the same range as this result.
Placebo arms in knee studies commonly report 30–60% of participants improving. An uncontrolled 87.5% sits above that band, but without a comparison arm there is no way to separate the compound from the injection, the attention, the passage of time, or the phrasing of the question.
Despite the robust preclinical findings, human data are extremely limited, no large-scale randomized trials exist, and BPC-157 should be considered investigational pending well-designed clinical trials.
McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025The wider ratio makes the same point. A 2025 systematic review counted 36 studies of BPC-157: 35 preclinical and 1 clinical. The one clinical entry is the phone survey. See BPC-157 benefits.
GLOW Blend
The three-compound blend discussed here, co-lyophilized, with a third-party certificate of analysis matched to the lot.
What about the skin photos?
Most GLOW before-and-after images are skin, not knees, and they are borrowing from a different literature again: GHK-Cu.
GHK-Cu does have replicated human evidence for skin. Serum GHK falls from around 200 ng/mL at age 20 to about 80 ng/mL by 60, and controlled dermal work reports real remodeling effects.
A number of clinical studies confirmed GHK-Cu’s ability to improve appearance of aging skin.
Pickart & Margolina, International Journal of Molecular Sciences, 2018That sentence is doing a lot of work in this category, and it describes topical application. Injected GHK-Cu has no published randomized human trial. A photograph of skin improving after a topical study is not evidence for an injected blend. We separate the two routes in injectable vs topical GHK-Cu and cover the results question directly in GHK-Cu before and after.
How to read any GLOW before-and-after
Four questions, and they take under a minute:
- Was anything measured, or was it photographed? A photo has no baseline, no lighting control and no comparison.
- Which compound was actually given? Almost every number in circulation belongs to one ingredient, usually BPC-157 or topical GHK-Cu.
- Was there a control arm? Without one, an improvement rate is not an effect size.
- What else changed? People starting a blend usually change other things at once. KLOW vs GLOW covers the four-compound version of the same problem.
For contrast, a peptide with a genuine measured before and after looks like tesamorelin: a CT scan, a randomized trial, 412 people, and a change that is smaller than the internet implies. That is what the evidence looks like when it exists.
GLOW Blend
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Controlled trials of the GLOW blend number zero. No study has given the three compounds together in any species.
- The nearest human data is a 2021 retrospective review of 17 knee patients given BPC-157, not the blend.
- Its outcome measure was a phone call: 16 reached, 14 reporting relief, no controls and no imaging.
- The placebo response in knee studies runs 30–60%, which is why an uncontrolled 87.5% cannot be read as an effect.
- Skin before-and-afters are borrowing GHK-Cu's topical evidence for an injected product.
What we're watching
The study that would change this page is not expensive: the blend against each constituent alone, on one endpoint, in one species. Nobody has run it. Closer to hand, both 2025 BPC-157 reviews call explicitly for a controlled dose-finding trial, and that would give the compound behind most of these claims its first real before and after. We are also watching for a randomized trial of injected GHK-Cu, which would settle whether the skin evidence transfers to the route this blend uses.
Frequently asked questions
Are GLOW peptide before and after photos real?
Some are real photographs. None of them are evidence. There is no baseline, no control, no standardized lighting and no way to know what else changed. The published human record behind this blend is one retrospective chart review with a phone survey as its outcome measure.
What did the 17-patient study actually find?
That 14 of 16 patients reachable by phone, six to twelve months after intra-articular BPC-157 for knee pain, said they felt better. That is 87.5%. There was no control arm, no validated outcome measure and no imaging, and the clinic surveyed its own patients.
How long does GLOW take to work?
No study has given the blend, so there is no measured onset. Any timeline in circulation was reconstructed from the separate constituents, two of which have no published human dose at all.
Does GLOW work for skin?
Unknown for the blend. GHK-Cu has replicated human evidence for skin remodeling when applied topically, which is not the route this vial uses. Injected GHK-Cu has no published randomized trial.
Why is the placebo rate relevant?
Because knee pain responds strongly to placebo. Controlled studies commonly report 30-60% of placebo participants improving. Without a comparison arm, an 87.5% response rate cannot be separated from that effect.
References
- Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13. PMID 34324435
- Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4). https://doi.org/10.1177/15563316251355551
- McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611–619. https://doi.org/10.1007/s12178-025-09990-7
- Seiwerth, S., Milavic, M., Vukojevic, J., et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533
- Dou, Y., Lee, A., Zhu, L., et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics, 2(1), 58–61. https://doi.org/10.31491/apt.2020.03.014
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015, 648108. https://doi.org/10.1155/2015/648108
- Dymek, M., Warszyński, P., & Sikora, E. (2023). GHK Peptide Permeability and Its Effects in Anti-Aging Skincare Topical Formulations. Pharmaceutics, 15(10), 2485. https://doi.org/10.3390/pharmaceutics15102485
- Philp, D., Goldstein, A. L., & Kleinman, H. K. (2004). Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development, 125(2), 113–115. https://doi.org/10.1016/j.mad.2003.11.005
- Ying, Y., Lin, C., Tao, N., et al. (2023). Thymosin β4 and actin: Binding modes, biological functions and clinical applications. Current Protein and Peptide Science, 24(1), 78–88. https://doi.org/10.2174/1389203724666221201093500